# Cogent Biosciences, Inc.: Form 10-Q for the period ended Sep 30, 2024

- Company: [Cogent Biosciences, Inc.](/companies/cogt.md) (CIK 1622229)
- Form: 10-Q
- Filed: 2024-11-12
- Accepted by EDGAR: Nov 12, 2024, 09:08 ET
- Period: 2024-09-30
- Accession: 0000950170-24-124712
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1622229/000095017024124712/cogt-20240930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1622229/000095017024124712/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2024-07-01 to 2024-09-30 | $63.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2024-01-01 to 2024-09-30 | $170.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2024-07-01 to 2024-09-30 | −$75.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-01-01 to 2024-09-30 | −$202.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2024-07-01 to 2024-09-30 | −$70.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-01-01 to 2024-09-30 | −$187.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-07-01 to 2024-09-30 | −$0.64 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-01-01 to 2024-09-30 | −$1.85 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-07-01 to 2024-09-30 | −$0.64 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-01-01 to 2024-09-30 | −$1.85 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-07-01 to 2024-09-30 | 110,165,580 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-01-01 to 2024-09-30 | 101,435,402 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-01-01 to 2024-09-30 | −$147.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2024-01-01 to 2024-09-30 | $498.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-09-30 | $97.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-09-30 | $341.5m | us-gaap:AssetsCurrent |
| Total assets | at 2024-09-30 | $384.0m | us-gaap:Assets |
| Current liabilities | at 2024-09-30 | $53.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-09-30 | $69.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2024-09-30 | $314.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1622229/000095017024124712/cogt-20240930.htm

Filed Nov 12, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-124712. Last ingested by Listed: Nov 5, 2026, 18:48 ET. No prices; not investment advice.